Source:http://linkedlifedata.com/resource/pubmed/id/11349434
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0013125,
umls-concept:C0024554,
umls-concept:C0034693,
umls-concept:C0043227,
umls-concept:C0085752,
umls-concept:C0178602,
umls-concept:C0178784,
umls-concept:C0205070,
umls-concept:C0205171,
umls-concept:C0205341,
umls-concept:C0220825,
umls-concept:C0282116,
umls-concept:C0405581,
umls-concept:C0600688,
umls-concept:C0748342,
umls-concept:C1441672,
umls-concept:C1442465,
umls-concept:C2603343
|
pubmed:dateCreated |
2001-5-14
|
pubmed:abstractText |
The present study was performed to clarify whether toxic effects of the antitumor drug, adriamycin (ADR) on the male genital organ can be adequately detected 2 and 4 weeks after a single intravenous administration in the rat. ADR was intravenously administered once to 10 Crj:CD (SD) male rats/group aged 6 weeks (4-week group) and 8 weeks (2-week group) at doses of 0, 2 and 6 mg/kg. The rats were sacrificed at the age of 10 weeks. For comparison 10 rats/group were killed 2 weeks after a single intravenous administration at the age of 4 weeks (immature group). Saline was administered to control rats. Histopathological examination and a quantitative morphometry were carried out after measurement of testes weights at necropsy. In rats of the 4-week and 2-week groups, mean absolute testicular weight in all groups was significantly decreased. However, changes in mean relative weight were not evident in the 2-week group. Disappearance of seminiferous epithelial cells was observed histopathologically in rats dosed with 2 and 6 mg/kg in the 2-week group. The change was more severe in the 4-week group, when reduction of spermatogenesis and giant cells were also observed at 6 mg/kg. The quantitative morphometry in the 2-week group showed decreases in the numbers of spermatogonia and spermatocytes in stages X and XII at 2 mg/kg, and in the numbers of spermatogonia in all stages and spermatocytes in all stages except stage V at 6 mg/kg. Moreover, the numbers of spermatogonia and spermatocytes in all stages and spermatids in stages II-III and V were decreased with dose related manner in the 4-week group. In contrast, no obvious change in testes weights was apparent in the immature group. However, the numbers of spermatogonia and spermatocytes in all stages were decreased at 6 mg/kg. In conclusion, testicular toxicity of ADR could be detected 2 weeks after a single administration. Susceptibility of the testes of immature rats to ADR might be less than that of older animals.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0388-1350
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
25 Spec No
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
103-15
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11349434-Animals,
pubmed-meshheading:11349434-Antineoplastic Agents,
pubmed-meshheading:11349434-Cell Count,
pubmed-meshheading:11349434-Dose-Response Relationship, Drug,
pubmed-meshheading:11349434-Doxorubicin,
pubmed-meshheading:11349434-Hematologic Tests,
pubmed-meshheading:11349434-Injections, Intravenous,
pubmed-meshheading:11349434-Male,
pubmed-meshheading:11349434-Organ Size,
pubmed-meshheading:11349434-Random Allocation,
pubmed-meshheading:11349434-Rats,
pubmed-meshheading:11349434-Rats, Sprague-Dawley,
pubmed-meshheading:11349434-Seminiferous Epithelium,
pubmed-meshheading:11349434-Spermatogenesis,
pubmed-meshheading:11349434-Testis,
pubmed-meshheading:11349434-Time Factors,
pubmed-meshheading:11349434-Toxicity Tests,
pubmed-meshheading:11349434-Weight Gain
|
pubmed:year |
2000
|
pubmed:articleTitle |
Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 10). Testicular toxicity of adriamycin observed 2 and 4 weeks after a single intravenous administration.
|
pubmed:affiliation |
Department of Toxicology & Safety Assessment, Kawanishi Pharma Research Institute, Nippon Boehringer Ingelheim Co., Ltd., 3-10-1 Yato, Kawanishi, Hyogo 666-0193, Japan.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|